International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
NCT02065765 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2025-01-09
Summary
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the compassionate use program.
Conditions
- Metastatic Gastric Cancer
- Metastatic Adenocarcinoma of the Gastroesophageal Junction
Interventions
- BIOLOGICAL
-
Administered intravenously (IV)
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- Austria
- Germany
- Greece
- Netherlands
- South Korea
Study Locations
More Related Trials
-
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
NCT02053376 ·Status: COMPLETED ·Phase: PHASE2
-
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
NCT02402036 ·Status: TERMINATED ·Phase: PHASE2
-
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
NCT06566755 ·Status: RECRUITING ·Phase: PHASE3
-
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
NCT00557102 ·Status: COMPLETED ·Phase: PHASE2
-
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
NCT06690281 ·Status: WITHDRAWN ·Phase: PHASE2
-
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
NCT00326495 ·Status: COMPLETED ·Phase: PHASE2
-
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
NCT04233567 ·Status: COMPLETED ·Phase: PHASE2
-
Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer
NCT07068763 ·Status: RECRUITING ·Phase: PHASE2
-
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
NCT01538680 ·Status: NO_LONGER_AVAILABLE
-
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
NCT03517956 ·Status: COMPLETED ·Phase: PHASE1
-
CyberKnife® for Hepatic Metastases From Colorectal Cancer
NCT01318447 ·Status: TERMINATED ·Phase: PHASE2
-
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
NCT05963490 ·Status: RECRUITING ·Phase: PHASE2
-
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment
NCT06137170 ·Status: COMPLETED
-
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
NCT04017650 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
NCT00362102 ·Status: COMPLETED ·Phase: PHASE2
-
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
NCT03657641 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
NCT02024607 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT03803553 ·Status: RECRUITING ·Phase: PHASE3
-
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
NCT02638766 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT02096354 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer
NCT02352571 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
NCT05818267 ·Status: RECRUITING ·Phase: NA
-
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
NCT03473756 ·Status: COMPLETED ·Phase: PHASE1
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
NCT04117945 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2